De-risking drug development: Key chemistry, manufacturing, and controls (CMC) and physiologically based pharmacokinetic (PBPK) approaches in early development Blog 降低药物开发风险:早期开发中的关键化学、制造和控制(CMC)及基于生理的药代动力学(PBPK)方法 2024 年 11 月 22 日 In drug development, early strategic planning is crucial to minimizing risks, optimizing…Certara2024 年 11 月 22 日
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen Poster 增强型确定性筛选设计为 CAR-T 细胞和淋巴清除疗法的 1 期筛选提供了高效率 Certara2024 年 11 月 22 日
Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials Poster Oncology MIDD Simulator — 用于早期肿瘤学试验总生存期预测的用户友好型应用程序 Certara2024 年 11 月 22 日
Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus Poster 系统性红斑狼疮中联合靶向 BAFF 和 CD40 通路的定量系统药理学模型 Certara2024 年 11 月 22 日
Population pharmacokinetic modeling of niraparib to assess different absorption models Poster 尼拉帕利(Niraparib)群体药代动力学建模以评估不同吸收模型 Certara2024 年 11 月 22 日
Why clinical pharmacology & pharmacometrics should collaborate Blog 临床药理学与定量药理学为何要合作 A symbiosis between a modeler and a trialist is often required to develop a model-informed…Certara2024 年 11 月 8 日
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体 Certara2024 年 11 月 7 日
Why you need an integrated development plan Blog 为什么需要药物综合发展计划? Learn about the Integrated Development Plan for successful drug development & its relation to the…Certara2024 年 10 月 17 日
Academic Centers of Excellence for Model-informed Drug Development (MIDD) Fact Sheet 模型引导的药物开发(MIDD)学术卓越中心 Certara2024 年 10 月 16 日